+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autoimmune Disease Therapeutics Market - Global Forecast to 2030- Product Image
Autoimmune Disease Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Autoimmune Disease Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4995356
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autoimmune Disease Therapeutics Market grew from USD 214.65 billion in 2024 to USD 231.15 billion in 2025. It is expected to continue growing at a CAGR of 7.76%, reaching USD 336.26 billion by 2030.

The autoimmune disease therapeutics landscape is characterized by rapid innovation in response to rising global prevalence and the complex interplay of genetic, environmental, and immunological factors. Advances in molecular biology and immunology have propelled the development of targeted interventions that aim to modulate aberrant immune responses with greater precision and fewer systemic side effects. Stakeholders across the healthcare continuum-from bench scientists to payers-are navigating a shifting ecosystem where personalized medicine, digital health integration, and outcome-driven reimbursement models are becoming foundational. As the industry seeks to address unmet needs in conditions ranging from rheumatoid arthritis to multiple sclerosis, collaboration between academia, biotech, and established pharmaceutical companies has never been more critical. This executive summary provides a concise yet thorough overview of the key dynamics transforming this therapeutic area, equipping decision-makers with the insights needed to drive strategic planning and investment in the coming years.

Transformative Shifts Driving Innovation and Patient-Centric Care

The transformative shifts reshaping autoimmune therapeutics are fueled by breakthroughs in biologics, gene editing, and small molecule innovations. Monoclonal antibodies and fusion proteins now target cytokine pathways with unprecedented specificity, while gene therapies offer the promise of durable remission through precise genomic correction. Concurrently, oral small molecules such as JAK inhibitors and corticosteroids have been optimized for improved safety profiles and patient adherence. Digital health platforms and wearable technologies are providing real-time monitoring of disease activity, enabling adaptive dosing strategies and personalized patient engagement. Value-based contracting models tied to clinical outcomes are gaining traction among payers, incentivizing manufacturers to demonstrate long-term efficacy and cost-effectiveness. As research paradigms shift toward combination regimens and adaptive trial designs, strategic partnerships between biotechs and large pharmaceutical companies are accelerating the translation of novel mechanisms into clinical practice. These converging trends are forging a more agile, patient-centric ecosystem that promises to redefine standards of care.

Assessing the Cumulative Impact of 2025 United States Tariffs

The implementation of new United States tariffs in 2025 is poised to introduce significant cost pressures across the autoimmune therapeutics supply chain. Import duties on biologic APIs and ancillary components may escalate production expenses, compelling manufacturers to reassess sourcing strategies and negotiate vertically integrated solutions. Small molecule drug developers could confront higher material costs for key intermediates, prompting a shift toward domestic manufacturing or alternate suppliers with favorable trade agreements. These tariff‐induced headwinds have the potential to accelerate price negotiations with payers and challenge margin sustainability for products nearing patent expiry. In response, companies may explore localized production hubs and invest in advanced manufacturing technologies such as continuous flow chemistry and single-use bioreactors to mitigate tariff impacts. Moreover, strategic alliances with contract development and manufacturing organizations (CDMOs) possessing diversified geographic footprints can buffer against regional policy fluctuations. By proactively addressing these supply chain vulnerabilities, industry leaders can maintain competitive positioning while safeguarding access for patients.

Key Segmentation Insights Across Therapeutic Types and End-Users

A nuanced understanding of market segmentation provides actionable clarity on therapeutic priorities and resource allocation. When examining the landscape by therapeutic type, antihyperglycemics and nonsteroidal anti-inflammatory drugs coexist alongside advanced biologics-spanning fusion proteins, gene therapies, and monoclonal antibodies-while small molecules further differentiate into corticosteroids and JAK inhibitors. Disease-specific insights reveal distinct innovation trajectories in inflammatory bowel disease, psoriasis, multiple sclerosis, lupus erythematosus, rheumatoid arthritis, and type 1 diabetes, with tailored mechanisms addressing each pathology’s unique immunological signature. Route of administration segmentation underscores the predominance of injectable formulations-including intramuscular, intravenous, and subcutaneous delivery-alongside oral therapies that enhance patient convenience and adherence. Therapeutic application analysis highlights strategies aimed at altering disease progression, modulating immune responses, managing pain, and reducing inflammation through targeted interventions. Finally, end-user patterns in ambulatory surgical centers, hospitals, and research institutes illuminate variations in procurement cycles, formulary considerations, and clinical trial collaborations. This integrated segmentation framework guides stakeholders in prioritizing R&D investment and market access strategies.

Key Regional Insights Highlighting Market Entry and Growth Drivers

Regional dynamics exhibit both convergence around global best practices and divergence driven by local policies, epidemiology, and infrastructure maturity. In the Americas, robust innovation pipelines and well-established reimbursement pathways in the United States catalyze rapid adoption of next-generation therapies, while Latin American markets present emerging opportunities amid evolving regulatory harmonization and growing patient awareness. Europe, the Middle East & Africa combine stringent regulatory frameworks in the EU with variable access landscapes in emerging markets, prompting tailored pricing and market entry models. Collaborative efforts across the Gulf Cooperation Council and pan-African regulatory initiatives are paving the way for streamlined approvals and cross-border clinical research. Meanwhile, Asia-Pacific is distinguished by high-growth markets such as China and India, where domestic biopharma champions are investing heavily in biosimilars and novel immunomodulators, and by developed markets like Japan and Australia that maintain leading roles in precision medicine adoption. This regional mosaic demands differentiated strategies to navigate reimbursement negotiations, supply chain logistics, and patient support programs effectively.

Key Company Insights Across Pharmaceutical, Diagnostics, and Biotech Sectors

Market leadership is defined by an ecosystem of established pharmaceutical giants, specialist biologics developers, diagnostic innovators, and analytical laboratories. Industry stalwarts such as Abbott Laboratories and AbbVie Inc. continue to leverage expansive portfolios and strategic acquisitions, while Amgen Inc. and AstraZeneca PLC drive next-generation monoclonal antibody and gene therapy platforms. Diagnostic and laboratory services firms, including Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, and bioMérieux S.A., are enhancing biomarker discovery and assay precision to support personalized treatment paradigms. Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi S.A. maintain diversified pipelines spanning cytokine inhibitors to small molecule immunosuppressants, often entering co-development agreements with CDMOs and research labs. Johnson & Johnson Services, Inc., Thermo Fisher Scientific Inc., and Siemens Healthineers AG bolster the ecosystem with advanced diagnostics and digital health solutions, while specialists such as Exagen, Inc., Lupin Limited, Trinity Biotech PLC, UCB S.A., and Werfen S.A. address niche indications and emerging biomarkers. This constellation of players underscores a collaborative yet competitive environment where innovation alliances and value-creation partnerships are the keys to sustainable differentiation.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a multi-pronged strategy to thrive in this dynamic environment. First, investing in emerging modalities-such as gene editing platforms and next-generation biologics-will ensure sustained competitive advantage in high-unmet-need areas. Second, diversifying supply chains through geographically distributed manufacturing hubs and strategic CDMO partnerships will mitigate tariff and geopolitical risks. Third, engaging early with payers and health technology assessment bodies to define value-based contracts tied to real-world outcomes will accelerate formulary inclusion and reimbursement. Fourth, forging cross-sector alliances with diagnostic firms and digital health providers will enhance patient stratification, monitoring, and adherence solutions. Fifth, strengthening regional expertise to navigate heterogeneous regulatory and commercial landscapes-particularly in Asia-Pacific and the Middle East & Africa-will unlock incremental growth avenues. Finally, leveraging advanced analytics and artificial intelligence for R&D optimization and predictive pharmacovigilance can reduce time-to-market and improve safety profiles. By executing these actionable recommendations, organizations can position themselves at the forefront of autoimmune therapeutics innovation.

Conclusion: Charting a Sustainable Path Forward in Autoimmune Therapeutics

The autoimmune disease therapeutics sector is undergoing a profound evolution driven by scientific breakthroughs, shifting policy landscapes, and emerging market dynamics. A rigorous segmentation framework and regional analysis reveal where strategic investments can yield disproportionate returns, while awareness of tariff implications underscores the importance of supply chain resilience. Collaboration among pharmaceutical innovators, diagnostic specialists, payers, and digital health providers is essential to advance personalized treatment paradigms and deliver sustainable value. As industry leaders navigate this complex ecosystem, a clear focus on emerging modalities, diversified manufacturing, value-based contracting, and regional expertise will chart the course for continued success. The strategies outlined herein offer a cohesive blueprint for translating innovation into real-world impact and improving clinical outcomes for patients worldwide.

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Antihyperglycemics
  • Biologics
    • Fusion Proteins
    • Gene Therapy
    • Monoclonal Antibodies
  • Cytokine Inhibitors
  • Immunomodulators
  • Immunosuppressants
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Phosphodiesterase Inhibitors
  • Small Molecules
    • Corticosteroids
    • JAK Inhibitors
  • Inflammatory Bowel Disease
  • Lupus Erythematosus
  • Multiple Sclerosis
  • Psoriasis
  • Rheumatoid Arthritis
  • Type 1 Diabetes
  • Injectable
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Oral
  • Disease Progression Alteration
  • Immune System Modulation
  • Pain Management
  • Reduction of Inflammation
  • Ambulatory Surgical Centers
  • Hospitals
  • Research Institutes

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Autoimmune Disease Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB S.A.
  • Werfen S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autoimmune Disease Therapeutics Market, by Therapeutic Types
8.1. Introduction
8.2. Antihyperglycemics
8.3. Biologics
8.3.1. Fusion Proteins
8.3.2. Gene Therapy
8.3.3. Monoclonal Antibodies
8.4. Cytokine Inhibitors
8.5. Immunomodulators
8.6. Immunosuppressants
8.7. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
8.8. Phosphodiesterase Inhibitors
8.9. Small Molecules
8.9.1. Corticosteroids
8.9.2. JAK Inhibitors
9. Autoimmune Disease Therapeutics Market, by Disease Type
9.1. Introduction
9.2. Inflammatory Bowel Disease
9.3. Lupus Erythematosus
9.4. Multiple Sclerosis
9.5. Psoriasis
9.6. Rheumatoid Arthritis
9.7. Type 1 Diabetes
10. Autoimmune Disease Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.2.3. Subcutaneous
10.3. Oral
11. Autoimmune Disease Therapeutics Market, by Therapeutic Application
11.1. Introduction
11.2. Disease Progression Alteration
11.3. Immune System Modulation
11.4. Pain Management
11.5. Reduction of Inflammation
12. Autoimmune Disease Therapeutics Market, by End-User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Research Institutes
13. Americas Autoimmune Disease Therapeutics Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Autoimmune Disease Therapeutics Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. AbbVie Inc.
16.3.3. Amgen Inc.
16.3.4. AstraZeneca PLC
16.3.5. Beckman Coulter, Inc.
16.3.6. Bio-Rad Laboratories, Inc.
16.3.7. BioAgilytix Labs, LLC
16.3.8. bioMerieux S.A.
16.3.9. Bristol-Myers Squibb Company
16.3.10. Eli Lilly and Company
16.3.11. Exagen, Inc.
16.3.12. F. Hoffmann-La Roche Ltd.
16.3.13. GlaxoSmithKline PLC
16.3.14. Johnson & Johnson Services, Inc.
16.3.15. Lupin Limited
16.3.16. Merck & Co., Inc.
16.3.17. Novartis AG
16.3.18. Pfizer, Inc.
16.3.19. Sanofi S.A.
16.3.20. Siemens Healthineers AG
16.3.21. Thermo Fisher Scientific Inc.
16.3.22. Trinity Biotech PLC
16.3.23. UCB S.A.
16.3.24. Werfen S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 71. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 72. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 73. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 76. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 81. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 84. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 95. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 96. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 97. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 104. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 105. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 106. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 107. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 113. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 114. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 115. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 118. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 121. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 122. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 123. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 124. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 126. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 129. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 130. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 131. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 134. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 137. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 138. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 139. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 142. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 145. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 146. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 147. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 148. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 150. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 153. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 154. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 155. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 156. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 158. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 161. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 162. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 163. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 164. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 166. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 169. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 170. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 171. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 174. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 177. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 178. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 179. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 182. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 185. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 186. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 187. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 188. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 190. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 193. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 194. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 195. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 196. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 198. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 209. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 210. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 211. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 212. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 213. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 215. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 218. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 220. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 223. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 226. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 227. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 228. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 229. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 230. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 231. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 234. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 235. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 236. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 242. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 243. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 244. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 246. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 247. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 250. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 251. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 252. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 253. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 255. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 258. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 259. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 260. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 261. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 263. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 277. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 279. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 282. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 283. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 284. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 285. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 287. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 290. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 291. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 292. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 293. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 295. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
TABLE 298. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 299. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 300. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 301. QATAR AUTOIMMUN

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB S.A.
  • Werfen S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Autoimmune Disease Therapeutics - Global Strategic Business Report - Product Image

Autoimmune Disease Therapeutics - Global Strategic Business Report

  • Report
  • 456 Pages
  • Global
From
Autoimmune Drugs Market 2024-2028 - Product Image

Autoimmune Drugs Market 2024-2028

  • Report
  • 185 Pages
  • Global
From
Autoimmune Treatment Market Report 2025 - Product Image

Autoimmune Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Autoimmune Disorders Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Autoimmune Disorders Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 89 Pages
  • Global
From
2025 Global Forecast for Autoimmune Disease Therapeutics Market (2026-2031 Outlook)-High Tech Outlook Report - Product Image

2025 Global Forecast for Autoimmune Disease Therapeutics Market (2026-2031 Outlook)-High Tech Outlook Report

  • Report
  • 132 Pages
  • Global
From

About the Autoimmune Drug Market

The Autoimmune Drug market is a subset of Immune Disorders Drugs, which are used to treat a variety of conditions caused by an overactive immune system. These drugs are designed to reduce inflammation, suppress the immune system, and prevent the body from attacking its own tissues. Common autoimmune diseases that are treated with these drugs include rheumatoid arthritis, psoriasis, lupus, and multiple sclerosis. Autoimmune drugs are typically administered orally, intravenously, or topically, depending on the condition being treated. They can be used alone or in combination with other treatments, such as physical therapy or lifestyle changes. Notable companies in the Autoimmune Drug market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.